Back to test list

KMT2A FISH

Also known as: MLL (mixed-lineage leukaemia) FISH

Test category:

Oncology - Leukaemia

Use of test

Purpose:

MLL (also known as KMT2A) is located at 11q23. It can undergo gene fusion with a variety of partner genes in several types of acute leukaemia. This fusion carriers prognostic implications.

Utility:

Presence of an MLL fusion gene is typically associated with a poor prognosis.

Ethical considerations:

This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.

Methodology:

Fluorescent in situ hybridisation (FISH) analysis, using probes to identify fusion of MLL with various partner genes.

Requesting the test

Ordering:

This test is usually requested by a haematologist or oncologist.

Sample required:

0.5 mL bone marrow in transport media, or 10 mL blood in lithium heparin.

To help ensure the quality of the test, a genetic test should be done with a dedicated sample whenever possible i.e. a sample collected specifically for that test rather than a sample that is used for multiple tests.

We recommend that the patient or another adult check the labelling of request forms and sample tubes.

Turnaround time:

2 business days.

Price:

This test has a Medicare rebate which, subject to the requirements of the Medicare descriptor being met, may cover all or part of the cost.

Rebate:

The Medicare details, including descriptor and schedule fee, are listed under MBS item 73314.